Certuity LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Certuity LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 66.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,104 shares of the biopharmaceutical company’s stock after purchasing an additional 439 shares during the quarter. Certuity LLC’s holdings in Regeneron Pharmaceuticals were worth $970,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC increased its position in Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its position in Regeneron Pharmaceuticals by 76,169.5% during the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares in the last quarter. abrdn plc increased its position in Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Regeneron Pharmaceuticals by 129.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock valued at $190,170,000 after buying an additional 122,103 shares in the last quarter. Finally, TD Asset Management Inc increased its position in Regeneron Pharmaceuticals by 64.4% during the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock valued at $148,353,000 after buying an additional 70,628 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Truist Financial reissued a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Finally, Bank of America lifted their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $977.77.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,195 shares of company stock valued at $9,759,898. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $890.66 on Wednesday. The stock’s 50-day simple moving average is $945.77 and its 200-day simple moving average is $895.19. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a market capitalization of $97.76 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.56 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the business earned $10.96 earnings per share. The business’s revenue was up .6% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.